Search PubMed⌕ Search

Biomedical subjects

M G Mott

Publications and source records attributed to M G Mott.

At least 73 records · Page 4Linked to original sources
PubMed1983

An unusual intraosseous lesion with fibroblastic, osteoclastic, osteoblastic, aneurysmal and fibromyxoid elements. "Solid" variant of aneurysmal bone cyst.

Four examples are reported of an unusual noncystic intraosseous lesion which does not conform to any hitherto recognized entity and which can be mistaken, not only by the general histopathologist but by the osteoarticular pathologist, for a variety of other conditions, including sarcoma and giant-cell tumor. They were in patients aged 5 to 13 years; three in the spine, one in the ethmoid. Local excision, supplemented by low-dose radiotherapy in cases with cord compression, produced a satisfactory outcome in all cases. At presentation the radiologic findings were nonspecific but, following treatment, an eggshell rim of bone developed in those lesions which had been incompletely excised. Histologically, they are characterised by florid fibroblastic or fibrohistiocytic proliferation, osteoblastic differentiation with osteoid production, areas rich in osteoclast-type giant cells, aneurysmal sinusoids, and occasional foci of degenerate calcifying fibromyxoid tissue. Because this combination of histologic features can be found in the solid parts of aneurysmal bone cyst and in no other condition, at this centre we have regarded this lesion as a variant of aneurysmal bone cyst devoid of any cystic component.

Adolescent↗
PubMed1983

Lymphoblastic lymphoma: late relapse in childhood.

This report describes two children with lymphoblastic lymphoma who relapsed more than 2 1/2 years from diagnosis. Relapses occurred at seven and 20 months after completion of treatment. Their therapy consisted of an intensive pulse chemotherapy program combined with radiation therapy. Initial relapse after two years' treatment has been extremely rare in patients receiving contemporary chemotherapy programs, and two-year survival without disease has been considered a cure. These cases illustrate that late relapses can occur after intensive chemotherapy and that two-year disease-free survival must not be interpreted as a complete cure.

Antineoplastic Agents↗
PubMed1983

Ceftazidime in the treatment of febrile immunosuppressed children.

We carried out a pilot study using ceftazidime alone in the treatment of febrile, neutropenic children. A total of 16 episodes were treated before the study was re-evaluated and tobramycin was added. Nineteen episodes have now been treated with a combination of ceftazidime and tobramycin. Of the first group, seven episodes failed to respond to ceftazidime; in five resistant or only partially sensitive organisms were thought to be the cause of failure. The most serious problem was our inability to predict two severe staphylococcal infections only partially sensitive to ceftazidime. These initial findings led us to add tobramycin to the regimen and to conclude that ceftazidime is not an appropriate antibiotic as a single agent in this group of patients.

Adolescent↗
PubMed1983

A good prognosis group in childhood acute lymphoblastic leukaemia.

The records of 121 children presenting with acute lymphoblastic leukaemia between 1969 and 1982 were reviewed. The overall relapse free survival rate was 50%. However, girls presenting with a total white blood cell count of 20 X 10(9)/l or less (35% of all patients) had a particularly favourable prognosis with an 80% relapse-free survival rate at 12 years. The difference in prognosis between the sexes is confirmed but this difference is confined to the low initial white cell count group. We suggest that girls in this group should be excluded from the more intensive arms of new treatment protocols.

Child↗
PubMed1982

Benign mesenchymoma of the chest wall in infancy.

Chest wall mesenchymoma is a rare tumour in childhood and often presents in the neonatal period. In the past all patients have received surgical treatment with quite a high morbidity. We present here three further cases that presented in infancy, two of which received minimal therapy with good results in each case. We would propose from these cases that once the diagnosis has been established by biopsy that total surgical resection not be carried out unless cardiac or respiratory embarrassment is present.

Biopsy↗
PubMed1982

Intermittent combined chemotherapy with doxorubicin in recurrent childhood acute lymphoblastic leukemia.

A series of 14 children with bone marrow or testicular recurrence of acute lymphoblastic leukemia (ALL) and treated with pulsed combined chemotherapy incorporating doxorubicin is reviewed. All had been previously adequately treated according to established leukemia protocols. Median disease-free survival for the series is 46 weeks, overall survival 62 weeks, and the toxicity of the therapy relatively low. This compares favorably with other reports of treatment of relapsed ALL and supports the formulation of prospective trials to evaluate anthracyclines in initial induction and consolidation phases of treatment of childhood ALL.

Antineoplastic Agents↗
PubMed1981

Domperidone as an antiemetic in paediatric oncology.

Domperidone was evaluated as an antiemetic in the control of nausea and vomiting associated with the administration of cytotoxic chemotherapy for various malignancies in a paediatric population. The results indicate that it is an effective agent for this purpose, control having been reasonable or good in 47 of 58 drug trials. The optimum dose would appear to be 0.7 mg/kg per dose. The only toxicity noted was of pain at the site of intravenous administration if domperidone was not adequately diluted.

Antiemetics↗
PubMed1981

Combination chemotherapy of childhood non-Hodgkin's lymphomas.

The rationale for the treatment of the non-Hodgkin's lymphomas in childhood is discussed. Results from recent trials of combination chemotherapy are given, and the treatment strategy of the United Kingdom Children's Cancer Study Group is described.

Antineoplastic Agents↗
PubMed1980

Clinical, haematological, and radiological features of children presenting with lymphoblastic mediastinal masses.

During 1968-1978, 68 children presented in six centres in the United Kingdom with lymphoblastic mediastinal masses. The disease was classified as acute lymphoblastic leukaemia (ALL) in 49 children whose bone marrow aspirates contained > 20% lymphoblasts, and as lymphoma (Sternberg lymphosarcoma - LS) in 19 with < 20% marrow infiltration. Male predominated in both groups, and children with ALL had more visceromegaly and lymphadenopathy, lower haemoglobin levels and platelet counts, and higher white cell counts. The most common chest x-ray finding in both groups was a nonspecific anterior mediastinal mass, but the appearances varied considerably and could be classified into three categories, which are illustrated. Pleural effusions were present in 44%. Cell surface-marker studies showed T cell characteristics in 14 of the 17 patients tested. Response to treatment and complications, such as central nervous system (CNS) and testicular relapse, were similar in ALL and LS, and were related to the size of the initial tumour load. Median remission lengths were 37 weeks for ALL and 89 weeks for LS patients. Leukaemic transformation occurred in 47% of LS children. Compared with the outcome in ALL children without mediastinal mass, the results of treatment were poor, regardless of the protocol used, and prophylactic therapy to the CNS reduced the frequency of, but did not eliminate, CNS disease.

Adolescent↗
PubMed1979

Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia.

Serum methotrexate levels were measured for 5 h after oral intake in 11 children with acute lymphoblastic leukaemia. The curves obtained with the child's regular dose of methotrexate varied widely, and were independent of the doses used. Peak levels were found in samples taken up to 3h after ingestion, and ranged from 300 to 1250 ng/ml. In the doses used, methotrexate toxicity was present in one of the eleven children, and was associated with a delayed peak and a high 5-h methotrexate level. Individual drug metabolism could be an important factor in the response to treatment, and needs to be evaluated in the assessment of protocols.

Administration, Oral↗
PubMed1978

Sex and prognosis in childhood acute lymphoblastic leukaemia.

Prognostic factors at diagnosis were examined in 67 children who presented with acute lymphoblastic leukaemia in 1970-76 and received modern treatment, incorporating prophylactic cranial irradiation and maintenance chemotherapy for at least 2 years. The effects of age and white blood-cell (W.B.C.) count were evident as in many previously reported studies but comparison of lifetables showed that the duration of haematological remission and complete remission was significantly shorter for boys than for girls. The difference in their survival was not significant. The risk of haematological relapse for boys and significantly greater even when relapses associated with the central nervous system or testicular relapse were excluded. The sex differences were not adequately explained by differences in initial W.B.C. count or in age.

Age Factors↗
PubMed1978

Growth and hormonal status of children treated for acute lymphoblastic leukaemia.

Growth and hypothalamic-pituitary function have been studied in children in long-term remission from acute lymphoblastic leukaemia (ALL). All 14 children are growing and developing normally; in the 8 children in whom the hypothalamic pituitary axis was investigated endocrine function is normal. Continuing long-term review of these children is essential, but hypothalamic-pituitary investigation is required only when there is a decrease in growth velocity or delay in the onset of puberty.

Adolescent↗